This study is comparing therapy with an investigational drug called inotuzumab ozogamicin, given in combination with rituximab (an approved drug), to treat patients with aggressive non-Hodgkin lymphoma (NHL) that has returned despite or stopped responding to other therapies. Patients in this study are not candidates for intensive high-dose chemotherapy because of their age or current health status.
Inotuzumab ozogamicin is an antibody that targets a protein on NHL cells called CD22. The antibody is attached to a toxin called calicheamicin that can enter and kill NHL cells. Patients in this study will be randomly assigned to receive inotuzumab plus rituximab (the latter drug being a standard therapy for NHL) or one of two standard treatment regimens (rituximab/bendamustine or rituximab/gemcitabine).